Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Wolfe Research assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research report issued ...

TwoStep Therapeutics Unveils Its Lead Tumor-Targeted Drug Conjugate and New Radiopharmaceutical Program at Debut Scientific ...

Objective To study the role of α4β7 integrin for gut homing of monocytes and to explore the biological consequences of therapeutic α4β7 inhibition with regard to intestinal wound healing. Design We ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...

Xintela's interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically s ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...